141 related articles for article (PubMed ID: 9163612)
1. Thrombopoietin-responsive essential thrombocythaemia with myelofibrosis.
Ozaki S; Kosaka M; Ozaki K; Wakatsuki S; Hashimoto T; Miyazaki H
Br J Haematol; 1997 May; 97(2):449-52. PubMed ID: 9163612
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity of megakaryocyte progenitors to thrombopoietin in essential thrombocythemia.
Kawasaki H; Nakano T; Kohdera U; Kobayashi Y
Am J Hematol; 2001 Nov; 68(3):194-7. PubMed ID: 11754402
[TBL] [Abstract][Full Text] [Related]
3. Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients.
Vicari L; Martinetti D; Buccheri S; Colarossi C; Aiello E; Stagno F; Villari L; Cavalli M; Di Raimondo F; Gulisano M; De Maria R; Vigneri P
Br J Haematol; 2012 Oct; 159(2):237-40. PubMed ID: 22924455
[No Abstract] [Full Text] [Related]
4. Spontaneous proliferative megakaryocytopoiesis and platelet hyperreactivity in essential thrombocythemia: is thrombopoietin the link?
Bellucci S; Michiels JJ
Ann Hematol; 2000 Feb; 79(2):51-8. PubMed ID: 10741915
[TBL] [Abstract][Full Text] [Related]
5. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.
Wagner-Ballon O; Chagraoui H; Prina E; Tulliez M; Milon G; Raslova H; Villeval JL; Vainchenker W; Giraudier S
J Immunol; 2006 Jun; 176(11):6425-33. PubMed ID: 16709799
[TBL] [Abstract][Full Text] [Related]
6. Endogenous megakaryocytic colony formation and thrombopoietin sensitivity of megakaryocytic progenitor cells are useful to distinguish between essential thrombocythemia and reactive thrombocytosis.
Mi JQ; Blanc-Jouvan F; Wang J; Sotto MF; Cousin F; Castinel A; Chauvet M; Sotto JJ; Polack B; Mossuz P
J Hematother Stem Cell Res; 2001 Jun; 10(3):405-9. PubMed ID: 11454315
[TBL] [Abstract][Full Text] [Related]
7. Myelofibrosis: experimental models and human studies.
Taskin AL; Cohen-Solal K; Le Couedic JP; Abina MA; Villeval JL; Debili N; Casadevall N; Vainchenker W; Wendling F
Stem Cells; 1998; 16 Suppl 2():155-64. PubMed ID: 11012187
[TBL] [Abstract][Full Text] [Related]
8. GpIIb/IIIa+ subpopulation of rat megakaryocyte progenitor cells exhibits high responsiveness to human thrombopoietin.
Kato T; Horie K; Hagiwara T; Maeda E; Tsumura H; Ohashi H; Miyazaki H
Exp Hematol; 1996 Aug; 24(10):1209-14. PubMed ID: 8765496
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis.
Evrard S; Bluteau O; Tulliez M; Rameau P; Gonin P; Zetterberg E; Palmblad J; Bonnefoy A; Villeval JL; Vainchenker W; Giraudier S; Wagner-Ballon O
Blood; 2011 Jan; 117(1):246-9. PubMed ID: 20944070
[TBL] [Abstract][Full Text] [Related]
10. [In vitro autonomous growth of megakaryocytic progenitors and the role of thrombopoietin (Tpo) in essential thrombocythemia].
Li Y; Brière J; Zhai M
Zhonghua Xue Ye Xue Za Zhi; 2001 Jun; 22(6):300-2. PubMed ID: 11877088
[TBL] [Abstract][Full Text] [Related]
11. Extramedullary haematopoietic tumour of the breast: a case report in a woman with secondary myelofibrosis following essential thrombocythaemia.
Al-Nafussi A; Al-Okati D; Alsewan M
Histopathology; 2004 Jun; 44(6):625-6. PubMed ID: 15186279
[No Abstract] [Full Text] [Related]
12. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation.
Yan XQ; Lacey D; Hill D; Chen Y; Fletcher F; Hawley RG; McNiece IK
Blood; 1996 Jul; 88(2):402-9. PubMed ID: 8695786
[TBL] [Abstract][Full Text] [Related]
13. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis.
Akiyama T; Matsunaga T; Terui T; Miyanishi K; Tanaka I; Sato T; Kuroda H; Takimoto R; Takayama T; Kato J; Yamauchi N; Kogawa K; Sakamaki S; Hirayama Y; Kohda K; Niitsu Y
Leukemia; 2005 Sep; 19(9):1558-66. PubMed ID: 16034467
[TBL] [Abstract][Full Text] [Related]
14. Megakaryocytes and platelets in myeloproliferative disorders.
Briere J; Kiladjian JJ; Peynaud-Debayle E
Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocytes and myelofibrosis in gray platelet syndrome.
Caen JP; Deschamps JF; Bodevin E; Bryckaert MC; Dupuy E; Wasteson A
Nouv Rev Fr Hematol (1978); 1987; 29(2):109-14. PubMed ID: 3615193
[TBL] [Abstract][Full Text] [Related]
16. Essential thrombocythemia: impaired regulation of megakaryocyte progenitors.
Zauli G; Catani L; Gugliotta L; Gaggioli L; Vitale L; Belmonte MM; Aglietta M; Bagnara GP
Int J Cell Cloning; 1991 Jan; 9(1):43-56. PubMed ID: 2010654
[TBL] [Abstract][Full Text] [Related]
17. Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount, in patients with essential thrombocythaemia.
Zauli G; Visani G; Catani L; Vianelli N; Gugliotta L; Capitani S
Br J Haematol; 1993 Jan; 83(1):14-20. PubMed ID: 8435322
[TBL] [Abstract][Full Text] [Related]
18. Proliferative properties of human umbilical cord blood megakaryocyte progenitor cells to human thrombopoietin.
Hagiwara T; Kodama I; Horie K; Kato T; Miyazaki H
Exp Hematol; 1998 Mar; 26(3):228-35. PubMed ID: 9502619
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
